With the rising prices of cancer treatment, the issue of patient access and affordability is gaining increased attention. Members of the Center explore elements of the pharmaceutical pricing and reimbursement policy landscape; system level features that result in higher patient out of pocket costs and overall healthcare spending; and study reforms of drug pricing and health insurance coverage to improve patient access. Some approaches include developing pathways for value based pricing, regulating the market use of rebates and reducing drug waste.
Cost of one month of treatment for an adult for each new cancer drug approved by the United States Food and Drug Administration, based on Medicare reimbursement rates and by year of drug approval.
Dusetzina SB, Conti RM, Yu NL, Bach PB. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. JAMA Intern Med. 2017 Aug 1;177(8):1185-1188. doi: 10.1001/jamainternmed.2017.1885.
Prasad V, De Jesús K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017 Jun;14(6):381-390. doi: 10.1038/nrclinonc.2017.31. Epub 2017 Mar 14. Review.